-
Adams MJ, Lipshultz SE.
Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention.
Pediatric Blood Cancer 2005;44:600-606.
-
Bene MC et al.
Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).
Leukemia 1995;9:1783-1786.
-
Biondi A et al.
Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction.
Blood 1992;80:492-497.
-
Buckley JD et al.
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Cancer 1989;63:1457-1465.
-
Creutzig U et al.
Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.
J Clin Oncol 1993;11:279-286.
-
Creutzig U et al.
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Leukemia 1996;10:1677-1686.
-
Creutzig U et al.
Risk factors for survival in children with refractory AML treated according to AML relapse strategies.
Haematol Blood Transfus 1997;39:810-817.
-
Creutzig U, Baumann M.
Spontaneous remission in neonates with Down's syndrome and acute myelogenous leukemia - transient myeloproliferative disease.
Onkologie 1998;21:124-128.
-
Creutzig U et al.
Definition of a standard-risk group in children with AML.
Br J Haematol 1999;104:630-639.
-
Creutzig U et al.
Extramedullary leukemia predicts unfavorable prognosis in children with AML: Experience of the AML-BFM studies in 974 children with de novo AML.
Blood 2001a;98(Suppl):11.
-
Creutzig U et al.
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93.
J Clin Oncol 2001b;19:2705-2713.
-
Creutzig U et al.
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Leukemia 2005a;19:1355-1360.
-
Creutzig U et al.
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Leukemia 2005b;19:2030-2042.
-
Creutzig U, Reinhardt D.
Akute myeloische Leukämien.
In: Gadner H, Gaedicke G, Niemeyer C, Ritter J.
Pädiatrische Hämatologie und Onkologie, 690-714.
Springer Verlag, Berlin, Heidelberg, New York, 2005c.
-
Creutzig U et al.,
Results of study AML-BFM 98 in children and adolescents with acute myeloid leukemia: less toxicity by optimizing chemotherapy, but not by addition of G-CSF.
J Clin Oncol 2006;24:4499-4506.
-
Dastugue N et al.
Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.
Leukemia 1995;9:1491-1498.
-
Fenaux P et al.
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.
Blood 1999;94:1192-1200.
-
Giantris A et al.
Anthracycline-induced cardiotoxicity in children and young adults.
Crit Rev Oncol Hematol 1998;27:53-68.
-
Grenier MA, Lipshultz SE.
Epidemiology of anthracycline cardiotoxicity in children and adults.
Semin Oncol 1998;25:72-85.
-
Hasle H.
Pattern of malignant disorders in individuals with Down's syndrome.
Lancet Oncol 2001;2:429-436.
-
Kaspers GJ, Creutzig U.
Pediatric acute myeloid leukemia: international progress and future directions.
Leukemia 2005;19:2025-2029.
-
Kremer LC et al.
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
Ann Oncol 2002;13:819-829.
-
Li FP, Bader JL.
Epidemiology of cancer in childhood.
In: Nathan DG, Oski FA.
Hematology of infancy and childhood, 1102-1119.
Saunders, Philadelphia, 1993.
-
Li Z et al.
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Nat Genet 2005;37:613-619.
-
Lie SO et al.
Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials.
Br J Haematol 2003;122:217-225.
-
Lo Coco F et al.
Acute promyelocytic leukemia: a curable disease.
Leukemia 1998;12:1866-1880.
-
Ludwig WD et al.
Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.
Recent Results Cancer Res 1993;131:269-282.
-
Mandelli F et al.
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Blood 1997;90:1014-1021.
-
National Cancer Institute.
SEER Cancer Statistics Review, 1975-2000.
http://seer.cancer.gov/csr/1975_2000 (15.08.2006)
-
Ravindranath Y et al.
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Blood 1992;80:2210-2214.
-
Rosen RB, Kang SJ.
Congenital agranulocytosis terminating in acute myelomonocytic leukemia.
J Pediatr 1979;94:406-408.
-
Schrappe M, Creutzig U.
Akute lymphoblastische Leukämie (ALL) und akute myeloische Leukämie (AML).
In: Garbe C et al.
Kurzgefasste interdisziplinäre Leitlinien 2006 (Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen), Deutsche Krebsgesellschaft, 525-537.
Zuckschwerdt, München, 2006.
-
Stevens RF et al.
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Br J Haematol 1998;101:130-140.
-
Taub JW et al.
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Blood 1999;94:1393-1400.
-
Thalhammer-Scherrer R et al.
The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination.
Am J Clin Pathol 2002;117:380-389.
-
Von Hoff DD et al.
Risk factors for doxorubicin-induced congestive heart failure.
Ann Intern Med 1979;91:710-717.
-
Wasser JS et al.
Congenital hypoplastic anemia (Diamond-Blackfan syndrome) terminating in acute myelogenous leukemia.
Blood 1978;51:991-995.
-
Wechsler J et al.
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Nat Genet 2002;32:148-152.
-
Zipursky A et al.
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.
Leuk Res 1994;18:163-171.
-
Zwaan CM et al.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Blood 2003;102:2387-2394.
Bildatlas Hämatologie
Druckversion
ISSN: 2193-6021
Zum Seitenanfang